Navigation Links
Post heart attack recovery may not be aided by stem cell injections, but trial demonstrates promise
Date:11/14/2011

CLEVELAND/ORLANDO University Hospitals Case Medical Center researchers could still be close to giving heart attack patients a second chancejust not as they originally thought.

LateTIME was a study of adult stem cells (autologous) harnessed from bone marrow that were believed to have the ability to improve heart function after an attack if injected into the heart within two weeks of the attack. Results are being released today at American Heart Association Scientific Sessions and published this week in Journal of the American Medical Association (JAMA).

The results have shown the injections within that timeframe were not favorable, but the concept showed great promise, according to an accompanying JAMA editorial that assessed the trial.

The therapy still shows promise for recovering lost or damaged heart tissue resulting from a heart attack. Both UH Case Medical Center's Drs. Dan Simon and Marco Costa, co-investigators in the LateTIME study, are currently participating in a similar trial, "TIME" that already has reduced the time between attack and stem cell injection.

The pair is optimistic the time variable adjustment in the new trial will lend favorable outcomes. Dr. Simon is Chief, Cardiovascular Medicine at UH Case Medical Center and the Herman K. Hellerstein Professor of Cardiovascular Research, Case Western Reserve School of Medicine. Dr. Costa is the director of the Interventional Cardiovascular Center and Research & Innovation Center at UH Case Medical Center as well as a professor of medicine at Case Western Reserve University School of Medicine.

The shared theories in both trials is that the specialized cells could have the ability to promote blood vessel growth, prevent cell death and transform themselves into a number of tissues, including muscle. After an acute heart attack, a remodeling process was initiated in the heart in an attempt to compensate for the damaged areas.

Researchers surmised that the condition of the heart muscle several weeks after the attack may differ considerably from the heart muscle in the acute stage setting. For some patients delaying the delivery of stem cells by two to three weeks may have been better than initiating the treatment during the acute phase.

All patients underwent baseline assessments that included medical history, physical exam, electrocardiogram, blood draws, echocardiogram and MRI tests. Participants were then assigned randomly to receive the stem cells or placebo within the aforementioned two to three week timeline.

The morning of stem cell or placebo infusion, a blood draw and bone marrow aspiration procedure of the hip bone are conducted to collect the stem cells. Later the same day, either stem cells or placebo are then infused through a catheter and directly into the damaged area of the heart.

Following the first 24 hours of the infusion, participants wear a small ECG machine, or Holter monitor. Additionally, patients record their body temperature twice a day for 30 days post infusion. Follow up visits at months one, three, six, 12 and 24 where baseline assessment testing are conducted.


'/>"/>

Contact: Mike Ferrari
mike.ferrari@uhhospitals.org
440-478-4563
University Hospitals Case Medical Center
Source:Eurekalert

Related biology news :

1. Results triple researchers projections with use of adult stem cells for heart failure
2. Low vitamin C levels may raise heart failure patients risk
3. Diseased hearts to heal themselves in future
4. Biologists use flies and mice to get to the heart of Down syndrome
5. Targeting leg fatigue in heart failure
6. Fatty acids involved in python heart growth could benefit diseased human heart
7. UM School of Medicine finds new pathway critical to heart arrhythmia
8. New study finds fetal heart rate not a good indicator of a babys health
9. Womens heart disease tied to small blood vessels
10. Einstein College of Medicine given $6.7 million to study congenital heart defect genetics
11. WPI mathematics professor Dalin Tang elected a Fellow of the American Heart Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, ... solutions for public safety, investigation, corrections and monitoring, announced ... smaller competitor, ICSolutions, to have an independent technology judge ... the most modern high tech/sophisticated telephone calling platform, and ... customers that they do most of what we do ...
(Date:11/15/2016)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... gut microbiome, today announced the pricing of an ... common stock and warrants to purchase 50,000,000 shares ... the public of $1.00 per share and accompanying ... offering, excluding the proceeds, if any from the ...
(Date:6/27/2016)... Research and Markets has announced the addition of the ... The report forecasts the biometrics ... a CAGR of 12.28% during the period 2016-2020. ... with inputs from industry experts. The report covers the market landscape ... includes a discussion of the key vendors operating in this market. ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... MA (PRWEB) , ... December 02, 2016 , ... Robots ... Light Event on December 3rd, 2016. The event, which is held on the ... work with helping Americans with Disabilities back into the workplace. Suitable Technologies is partnering ...
(Date:12/2/2016)... December 2, 2016 The immunohistochemistry (IHC) ... at a CAGR of 7.3% during the forecast period of 2016 ... diagnostic laboratories segment accounted for the largest share of immunohistochemistry (IHC) ... , ... global immunohistochemistry (IHC) market spread across 225 pages, profiling 10 companies ...
(Date:11/30/2016)... ... November 30, 2016 , ... BEI Kimco, a brand ... a flexure design that ensures high alignment accuracy by preventing unwanted shaft rotation. ... suited where extreme precision is required, such as in medical equipment, laboratory instrumentation, ...
(Date:11/30/2016)... , November 30, 2016 ... a few players hold a dominant share in the ... River Laboratories International, Inc., and Merck KGaA, held a ... 2015. Transparency Market Research observes that these companies are ... on development products that are do not require rabbit ...
Breaking Biology Technology: